Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.
Why Budweiser Parent Anheuser-Busch InBev’s Shares Are Taking Off Today
Discover why Anheuser-Busch InBev is surging post-earnings! With a 2.6% sales growth in Q1 FY24, beating estimates, the beverage giant showcases resilience amid market shifts.